New approaches from nanomedicine for treating leishmaniasis

Página do item simplificado
dc.contributor.authorGutierrez, Victor
dc.contributor.authorSeabra, Amedea B. [UNIFESP]
dc.contributor.authorReguera, Rosa M.
dc.contributor.authorKhandare, Jayant
dc.contributor.authorCalderon, Marcelo
dc.date.accessioned2019-01-21T10:30:18Z
dc.date.available2019-01-21T10:30:18Z
dc.date.issued2016
dc.description.abstractLeishmaniasis, a vector-borne disease caused by obligate intramacrophage protozoa, threatens 350 million people in 98 countries around the world. There are already 12 million infected people worldwide and two million new cases occur annually. Leishmaniasis has three main clinical presentations: cutaneous (CL), mucosal (ML), and visceral (VL). It is considered an opportunistic, infectious disease and the HIV-leishmaniasis correlation is well known. Antimonial compounds are used as first-line treatment drugs, but their toxicity, which can be extremely high, leads to a number of undesirable side effects and resultant failure of the patients to adhere to treatment. There is also a reported increase in Leishmania sp. resistance to these drugs. Nanotechnology has emerged as an attractive alternative because of its improved bioavailability and lower toxicity, and other characteristics that help to relieve the burden of this disease. In this review we will present some of the recent advances in the nanotechnological research regarding the treatment of leishmaniasis. The preclinical results regarding the approaches for a biomedical treatment of the disease have been encouraging, but further efforts will still be necessary for this therapy to have greater clinical applicability in humans.en
dc.description.affiliationFree Univ Berlin, Inst Chem & Biochem, D-14195 Berlin, Germany
dc.description.affiliationUniv Fed Sao Paulo, Exact & Earth Sci Dept, Sao Paulo, Brazil
dc.description.affiliationUniv Leon, Dept Ciencias Biomed, E-24071 Leon, Spain
dc.description.affiliationMaharashtra Inst Pharm, Pune 411038, Maharashtra, India
dc.description.affiliationUnifespExact and Earth Sciences Department, Universidade Federal de São Paulo, Diadema, Brazil
dc.description.sourceWeb of Science
dc.description.sponsorshipFundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
dc.description.sponsorshipDeutsche Forschungsgemeinschaft (DFG)/German Research Foundation [SFB1112]
dc.description.sponsorshipBundesministerium fur Bildung und Forschung (BMBF) through the NanoMatFutur award [13N12561]
dc.description.sponsorshipHelmholtz Virtual Institute, Multifunctional Biomaterials for Medicine
dc.description.sponsorshipFreie Universitat Berlin Focus Area Nanoscale
dc.description.sponsorshipConselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)
dc.description.sponsorshipIDFAPESP: 2012/17053-7
dc.description.sponsorshipIDMCTI/CNPq: PI12/00104
dc.description.sponsorshipIDCYTED: 214RT0482
dc.format.extent152-168
dc.identifierhttp://dx.doi.org/10.1039/c5cs00674k
dc.identifier.citationChemical Society Reviews. Cambridge, v. 45, n. 1, p. 152-168, 2016.
dc.identifier.doi10.1039/c5cs00674k
dc.identifier.issn0306-0012
dc.identifier.urihttp://repositorio.unifesp.br/handle/11600/49687
dc.identifier.wosWOS:000367250700008
dc.language.isoeng
dc.publisherRoyal Soc Chemistry
dc.relation.ispartofChemical Society Reviews
dc.rightsinfo:eu-repo/semantics/restrictedAccess
dc.subjectLiposomal Amphotericin-Ben
dc.subjectSolid-Lipid Nanoparticlesen
dc.subjectHost Immune-Responseen
dc.subjectNitric-Oxide Donoren
dc.subjectCutaneous Leishmaniasisen
dc.subjectVisceral Leishmaniasisen
dc.subjectIn-Vitroen
dc.subjectDelivery-Systemsen
dc.subjectDna Vaccinationen
dc.subjectDendritic Cellsen
dc.titleNew approaches from nanomedicine for treating leishmaniasisen
dc.typeinfo:eu-repo/semantics/review
Arquivos
Coleções
ICAQF - Artigos